Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide.
Exceptional growth potential with mediocre balance sheet.
Share Price & News
How has Cassiopea's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CPPS.F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how CPPS.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CPPS.F performed against the US Market.
Price Volatility Vs. Market
How volatile is Cassiopea's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Cassiopea undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CPPS.F ($43.5) is trading below our estimate of fair value ($633.19)
Significantly Below Fair Value: CPPS.F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CPPS.F is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: CPPS.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CPPS.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CPPS.F is overvalued based on its PB Ratio (45.2x) compared to the US Pharmaceuticals industry average (2.9x).
How is Cassiopea forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CPPS.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: CPPS.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CPPS.F's is expected to become profitable in the next 3 years.
Revenue vs Market: CPPS.F's revenue (53% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: CPPS.F's revenue (53% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CPPS.F's Return on Equity is forecast to be very high in 3 years time (3367.4%).
How has Cassiopea performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPPS.F is currently unprofitable.
Growing Profit Margin: CPPS.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CPPS.F is unprofitable, and losses have increased over the past 5 years at a rate of -23% per year.
Accelerating Growth: Unable to compare CPPS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CPPS.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: CPPS.F has a negative Return on Equity (-146.12%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Cassiopea's financial position?
Financial Position Analysis
Short Term Liabilities: CPPS.F's short term assets (€2.9M) exceed its short term liabilities (€1.9M).
Long Term Liabilities: CPPS.F's short term assets (€2.9M) exceed its long term liabilities (€2.2M).
Debt to Equity History and Analysis
Debt Level: CPPS.F's debt to equity ratio (25.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CPPS.F's debt to equity ratio has reduced over the past 5 years.
Inventory Level: CPPS.F has a low level of unsold assets or inventory.
Debt Coverage by Assets: CPPS.F's debt is covered by short term assets (assets are 1.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CPPS.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CPPS.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -19.4% each year
What is Cassiopea's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CPPS.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CPPS.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CPPS.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPPS.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CPPS.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Diana Harbort (53yo)
Ms. Diana Harbort serves as the Chief Executive Officer of Cassiopea S.p.A. since 2015 and has been its Executive Director since May 2015. Ms. Harbort served as the Head of Corporate Development at Medicis ...
CEO Compensation Analysis
Compensation vs Market: Diana's total compensation ($USD300.43K) is below average for companies of similar size in the US market ($USD1.73M).
Compensation vs Earnings: Diana's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||5.1yrs||€276.15k||no data|
|CFO & Head of Investor Relations||5.1yrs||no data||no data|
|Chief Operating Officer||5.1yrs||no data||no data|
|Chief Scientific Officer||0yrs||no data||no data|
|Chief Medical Officer||3.1yrs||no data||no data|
|Finance Director||0yrs||no data||no data|
|Vice President of Marketing||1.1yrs||no data||no data|
|Vice President of Sales||0yrs||no data||no data|
Experienced Management: CPPS.F's management team is seasoned and experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cassiopea S.p.A.'s company bio, employee growth, exchange listings and data sources
- Name: Cassiopea S.p.A.
- Ticker: CPPS.F
- Exchange: OTCPK
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF407.000m
- Listing Market Cap: CHF417.055m
- Shares outstanding: 10.00m
- Website: https://www.cassiopea.com
Number of Employees
- Cassiopea S.p.A.
- Via Cristoforo Colombo, 1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SKIN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Jul 2015|
|0R8Y||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Jul 2015|
|CSP||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Jul 2015|
|SKINZ||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Registered Shares||GB||CHF||Jul 2015|
|CPPS.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Jul 2015|
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 02:01|
|End of Day Share Price||2020/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.